GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Interest Coverage

LTR Pharma (ASX:LTP) Interest Coverage : No Debt (1) (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. LTR Pharma's Operating Income for the six months ended in Dec. 2024 was A$-2.78 Mil. LTR Pharma's Interest Expense for the six months ended in Dec. 2024 was A$0.00 Mil. LTR Pharma has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

LTR Pharma Ltd has no debt.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for LTR Pharma's Interest Coverage or its related term are showing as below:

ASX:LTP' s Interest Coverage Range Over the Past 10 Years
Min: No Debt   Med: No Debt   Max: No Debt
Current: No Debt


ASX:LTP's Interest Coverage is ranked better than
98.87% of 354 companies
in the Biotechnology industry
Industry Median: 153.65 vs ASX:LTP: No Debt

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


LTR Pharma Interest Coverage Historical Data

The historical data trend for LTR Pharma's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

LTR Pharma Interest Coverage Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Interest Coverage
- No Debt No Debt No Debt

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23 Dec23 Jun24 Dec24
Interest Coverage Get a 7-Day Free Trial No Debt No Debt No Debt No Debt No Debt

Competitive Comparison of LTR Pharma's Interest Coverage

For the Biotechnology subindustry, LTR Pharma's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LTR Pharma's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LTR Pharma's Interest Coverage distribution charts can be found below:

* The bar in red indicates where LTR Pharma's Interest Coverage falls into.



LTR Pharma Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

LTR Pharma's Interest Coverage for the fiscal year that ended in Jun. 2024 is calculated as

Here, for the fiscal year that ended in Jun. 2024, LTR Pharma's Interest Expense was A$0.00 Mil. Its Operating Income was A$-6.99 Mil. And its Long-Term Debt & Capital Lease Obligation was A$0.00 Mil.

LTR Pharma had no debt (1).

LTR Pharma's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Here, for the six months ended in Dec. 2024, LTR Pharma's Interest Expense was A$0.00 Mil. Its Operating Income was A$-2.78 Mil. And its Long-Term Debt & Capital Lease Obligation was A$0.00 Mil.

LTR Pharma had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


LTR Pharma  (ASX:LTP) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


LTR Pharma Interest Coverage Related Terms

Thank you for viewing the detailed overview of LTR Pharma's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


LTR Pharma Business Description

Traded in Other Exchanges
N/A
Address
9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.

LTR Pharma Headlines

No Headlines